BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell. 2016;19:293-297. [PMID: 27588746 DOI: 10.1016/j.stem.2016.08.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev 2021;21:524-9. [PMID: 33997101 DOI: 10.1016/j.omtm.2021.04.001] [Reference Citation Analysis]
2 Roemhild A, Otto NM, Moll G, Abou-El-Enein M, Kaiser D, Bold G, Schachtner T, Choi M, Oellinger R, Landwehr-Kenzel S, Juerchott K, Sawitzki B, Giesler C, Sefrin A, Beier C, Wagner DL, Schlickeiser S, Streitz M, Schmueck-Henneresse M, Amini L, Stervbo U, Babel N, Volk HD, Reinke P. Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ 2020;371:m3734. [PMID: 33087345 DOI: 10.1136/bmj.m3734] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
3 Krause M, Phan TG, Ma H, Sobey CG, Lim R. Cell-Based Therapies for Stroke: Are We There Yet? Front Neurol 2019;10:656. [PMID: 31293500 DOI: 10.3389/fneur.2019.00656] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
4 Lindenberg MA, Retèl VP, van den Berg JH, Geukes Foppen MH, Haanen JB, van Harten WH. Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product. J Immunother 2018;41:413-25. [PMID: 30300260 DOI: 10.1097/CJI.0000000000000245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals. Mol Ther Methods Clin Dev 2020;18:269-79. [PMID: 32637456 DOI: 10.1016/j.omtm.2020.05.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
6 ten Ham RM, Hövels AM, Hoekman J, Frederix GW, Leufkens HG, Klungel OH, Jedema I, Veld SA, Nikolic T, Van Pel M, Zwaginga JJ, Lin F, de Goede AL, Schreibelt G, Budde S, de Vries IJM, Wilkie GM, Dolstra H, Ovelgönne H, Meij P, Mountford JC, Turner ML, Hoefnagel MH. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy 2020;22:388-97. [DOI: 10.1016/j.jcyt.2020.03.432] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
7 Michelsen S, Nachi S, Van Dyck W, Simoens S, Huys I. Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies. Front Pharmacol 2020;11:594446. [PMID: 33363468 DOI: 10.3389/fphar.2020.594446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Bauer G, Elsallab M, Abou-El-Enein M. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions. Stem Cells Transl Med. 2018;7:676-685. [PMID: 30063299 DOI: 10.1002/sctm.17-0282] [Cited by in Crossref: 66] [Cited by in F6Publishing: 49] [Article Influence: 22.0] [Reference Citation Analysis]
9 Abou-El-Enein M, Hey SP. Cell and Gene Therapy Trials: Are We Facing an 'Evidence Crisis'? EClinicalMedicine 2019;7:13-4. [PMID: 31193634 DOI: 10.1016/j.eclinm.2019.01.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
10 Abou-el-enein M, Cathomen T, Ivics Z, June CH, Renner M, Schneider CK, Bauer G. Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment. Cell Stem Cell 2017;21:427-30. [DOI: 10.1016/j.stem.2017.09.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
11 Abou-El-Enein M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev 2021;22:11-4. [PMID: 34377737 DOI: 10.1016/j.omtm.2021.06.012] [Reference Citation Analysis]
12 Coppens DG, De Bruin ML, Leufkens HG, Hoekman J. Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation. Clin Pharmacol Ther 2018;103:120-7. [DOI: 10.1002/cpt.894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
13 Qiu T, Wang Y, Dabbous M, Hanna E, Han R, Liang S, Toumi M. Current state of developing advanced therapies for rare diseases in the European Union. Expert Opinion on Orphan Drugs 2020;8:417-29. [DOI: 10.1080/21678707.2020.1835640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Calmels B, Mfarrej B, Chabannon C. From clinical proof-of-concept to commercialization of CAR T cells. Drug Discov Today 2018;23:758-62. [PMID: 29317339 DOI: 10.1016/j.drudis.2018.01.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
15 Iglesias-Lopez C, Obach M, Vallano A, Agustí A. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Cytotherapy 2021;23:261-74. [PMID: 33483292 DOI: 10.1016/j.jcyt.2020.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Cathomen T, Schüle S, Schüßler-Lenz M, Abou-El-Enein M. The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage? Trends Biotechnol 2019;37:120-3. [PMID: 30017092 DOI: 10.1016/j.tibtech.2018.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
17 Elsanhoury A, Sanzenbacher R, Reinke P, Abou-El-Enein M. Accelerating Patients' Access to Advanced Therapies in the EU. Mol Ther Methods Clin Dev 2017;7:15-9. [PMID: 28971109 DOI: 10.1016/j.omtm.2017.08.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
18 O'Donnell BT, Ives CJ, Mohiuddin OA, Bunnell BA. Beyond the Present Constraints That Prevent a Wide Spread of Tissue Engineering and Regenerative Medicine Approaches. Front Bioeng Biotechnol 2019;7:95. [PMID: 31134194 DOI: 10.3389/fbioe.2019.00095] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 12.5] [Reference Citation Analysis]
19 Abou-El-Enein M, Grainger DW, Kili S. Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence. Mol Ther 2018;26:1172-6. [PMID: 29685384 DOI: 10.1016/j.ymthe.2018.04.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
20 González-Nieto D, Fernández-García L, Pérez-Rigueiro J, Guinea GV, Panetsos F. Hydrogels-Assisted Cell Engraftment for Repairing the Stroke-Damaged Brain: Chimera or Reality. Polymers (Basel) 2018;10:E184. [PMID: 30966220 DOI: 10.3390/polym10020184] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
21 Wang Y, Qiu T, Liang S, Toumi M. An overview of cell and gene therapy development in China. Hum Gene Ther 2021. [PMID: 34235966 DOI: 10.1089/hum.2021.126] [Reference Citation Analysis]
22 Nguyen KN, Bobba S, Richardson A, Park M, Watson SL, Wakefield D, Di Girolamo N. Native and synthetic scaffolds for limbal epithelial stem cell transplantation. Acta Biomater 2018;65:21-35. [PMID: 29107055 DOI: 10.1016/j.actbio.2017.10.037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
23 Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. The path to successful commercialization of cell and gene therapies: empowering patient advocates. Cytotherapy 2017;19:293-8. [PMID: 27956199 DOI: 10.1016/j.jcyt.2016.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kavianpour M, Saleh M, Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm. Stem Cell Res Ther 2020;11:404. [PMID: 32948252 DOI: 10.1186/s13287-020-01849-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
25 Coppens DGM, de Wilde S, Guchelaar HJ, De Bruin ML, Leufkens HGM, Meij P, Hoekman J. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making. Cytotherapy 2018;20:769-78. [PMID: 29730080 DOI: 10.1016/j.jcyt.2018.03.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Mah N, Seltmann S, Aran B, Steeg R, Dewender J, Bultjer N, Veiga A, Stacey GN, Kurtz A. Access to stem cell data and registration of pluripotent cell lines: The Human Pluripotent Stem Cell Registry (hPSCreg). Stem Cell Research 2020;47:101887. [DOI: 10.1016/j.scr.2020.101887] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Fritsche E, Volk H, Reinke P, Abou-el-enein M. Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology 2020;38:1099-112. [DOI: 10.1016/j.tibtech.2019.12.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 26.0] [Reference Citation Analysis]
28 Gancberg D. Twenty Years of European Union Support to Gene Therapy and Gene Transfer. Hum Gene Ther 2017;28:951-3. [PMID: 28665213 DOI: 10.1089/hum.2017.110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
29 Jørgensen J, Kefalas P. Annuity payments can increase patient access to innovative cell and gene therapies under England's net budget impact test. J Mark Access Health Policy 2017;5:1355203. [PMID: 28839525 DOI: 10.1080/20016689.2017.1355203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
30 Argentati C, Tortorella I, Bazzucchi M, Morena F, Martino S. Harnessing the Potential of Stem Cells for Disease Modeling: Progress and Promises. J Pers Med. 2020;10. [PMID: 32041088 DOI: 10.3390/jpm10010008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
31 Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol 2020;21:e104-16. [PMID: 32007196 DOI: 10.1016/S1470-2045(19)30729-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 28.0] [Reference Citation Analysis]
32 Kim K, Bou-Ghannam S, Thorp H, Grainger DW, Okano T. Human mesenchymal stem cell sheets in xeno-free media for possible allogenic applications. Sci Rep 2019;9:14415. [PMID: 31595012 DOI: 10.1038/s41598-019-50430-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
33 Heine R, Thielen FW, Koopmanschap M, Kersten MJ, Einsele H, Jaeger U, Sonneveld P, Sierra J, Smand C, Uyl-de Groot CA. Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. Hemasphere 2021;5:e524. [PMID: 33880433 DOI: 10.1097/HS9.0000000000000524] [Reference Citation Analysis]
34 Yu TTL, Gupta P, Ronfard V, Vertès AA, Bayon Y. Recent Progress in European Advanced Therapy Medicinal Products and Beyond. Front Bioeng Biotechnol 2018;6:130. [PMID: 30298129 DOI: 10.3389/fbioe.2018.00130] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
35 Legallais C, Kim D, Mihaila SM, Mihajlovic M, Figliuzzi M, Bonandrini B, Salerno S, Yousef Yengej FA, Rookmaaker MB, Sanchez Romero N, Sainz-Arnal P, Pereira U, Pasqua M, Gerritsen KGF, Verhaar MC, Remuzzi A, Baptista PM, De Bartolo L, Masereeuw R, Stamatialis D. Bioengineering Organs for Blood Detoxification. Adv Healthc Mater 2018;7:e1800430. [PMID: 30230709 DOI: 10.1002/adhm.201800430] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
36 Green FR, Shubber NM, Koumpa FS, Hamilton NJI. Regenerative medicine for end-stage fibrosis and tissue loss in the upper aerodigestive tract: a twenty-first century review. J Laryngol Otol 2021;135:473-85. [PMID: 33988100 DOI: 10.1017/S002221512100092X] [Reference Citation Analysis]
37 Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res 2018;7:15-28. [PMID: 29144165 DOI: 10.2217/cer-2017-0068] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
38 Gavan SP, Lu CY, Payne K. Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. J Pers Med 2019;9:E28. [PMID: 31117188 DOI: 10.3390/jpm9020028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Eder C, Wild C. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption. J Mark Access Health Policy 2019;7:1600939. [PMID: 31069029 DOI: 10.1080/20016689.2019.1600939] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
40 Harrison RP, Ruck S, Medcalf N, Rafiq QA. Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities. Cytotherapy 2017;19:1140-51. [DOI: 10.1016/j.jcyt.2017.07.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
41 Yonesi M, Garcia-Nieto M, Guinea GV, Panetsos F, Pérez-Rigueiro J, González-Nieto D. Silk Fibroin: An Ancient Material for Repairing the Injured Nervous System. Pharmaceutics 2021;13:429. [PMID: 33806846 DOI: 10.3390/pharmaceutics13030429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Caplan H, Olson SD, Kumar A, George M, Prabhakara KS, Wenzel P, Bedi S, Toledano-Furman NE, Triolo F, Kamhieh-Milz J, Moll G, Cox CS Jr. Mesenchymal Stromal Cell Therapeutic Delivery: Translational Challenges to Clinical Application. Front Immunol 2019;10:1645. [PMID: 31417542 DOI: 10.3389/fimmu.2019.01645] [Cited by in Crossref: 84] [Cited by in F6Publishing: 63] [Article Influence: 42.0] [Reference Citation Analysis]
43 van Overbeeke E, Michelsen S, Toumi M, Stevens H, Trusheim M, Huys I, Simoens S. Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions. Drug Discov Today 2021;26:399-415. [PMID: 33242695 DOI: 10.1016/j.drudis.2020.11.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng 2021. [PMID: 33795852 DOI: 10.1038/s41551-021-00698-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
45 Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Front Immunol. 2020;11:1091. [PMID: 32574263 DOI: 10.3389/fimmu.2020.01091] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 47.0] [Reference Citation Analysis]
46 Morrow D, Ussi A, Migliaccio G. Addressing Pressing Needs in the Development of Advanced Therapies. Front Bioeng Biotechnol 2017;5:55. [PMID: 28993805 DOI: 10.3389/fbioe.2017.00055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
47 Papadaki M. Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients. Front Med (Lausanne) 2017;4:56. [PMID: 28611985 DOI: 10.3389/fmed.2017.00056] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
48 Pani L, Becker K. New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing. Clin Drug Investig 2021;41:529-37. [PMID: 34014509 DOI: 10.1007/s40261-021-01041-6] [Reference Citation Analysis]
49 Apaydin EA, Richardson AS, Baxi S, Vockley J, Akinniranye O, Ross R, Larkin J, Motala A, Azhar G, Hempel S. An evidence map of randomised controlled trials evaluating genetic therapies. BMJ Evid Based Med 2020:bmjebm-2020-111448. [PMID: 33172937 DOI: 10.1136/bmjebm-2020-111448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Thorp H, Kim K, Kondo M, Maak T, Grainger DW, Okano T. Trends in Articular Cartilage Tissue Engineering: 3D Mesenchymal Stem Cell Sheets as Candidates for Engineered Hyaline-Like Cartilage. Cells 2021;10:643. [PMID: 33805764 DOI: 10.3390/cells10030643] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Kim K, Thorp H, Bou-Ghannam S, Grainger DW, Okano T. Stable cell adhesion affects mesenchymal stem cell sheet fabrication: Effects of fetal bovine serum and human platelet lysate. J Tissue Eng Regen Med 2020;14:741-53. [PMID: 32212212 DOI: 10.1002/term.3037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
52 Jørgensen J, Mungapen L, Kefalas P. Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching. J Mark Access Health Policy 2019;7:1573164. [PMID: 30774785 DOI: 10.1080/20016689.2019.1573164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
53 Ten Ham RMT, Nievaart JC, Hoekman J, Cooper RS, Frederix GWJ, Leufkens HGM, Klungel OH, Ovelgönne H, Hoefnagel MHN, Turner ML, Mountford JC. Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy 2021;23:730-9. [PMID: 33593688 DOI: 10.1016/j.jcyt.2020.12.014] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Scavone C, di Mauro G, Mascolo A, Berrino L, Rossi F, Capuano A. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Front Pharmacol 2019;10:111. [PMID: 30814951 DOI: 10.3389/fphar.2019.00111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
55 Gardner J, Webster A, Barry J. Anticipating the clinical adoption of regenerative medicine: building institutional readiness in the UK. Regenerative Medicine 2018;13:29-39. [DOI: 10.2217/rme-2017-0121] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
56 Goula A, Gkioka V, Michalopoulos E, Katsimpoulas M, Noutsias M, Sarri EF, Stavropoulos C, Kostakis A. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. J Clin Med Res 2020;12:780-6. [PMID: 33447311 DOI: 10.14740/jocmr3964] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Childs PG, Reid S, Salmeron-Sanchez M, Dalby MJ. Hurdles to uptake of mesenchymal stem cells and their progenitors in therapeutic products. Biochem J 2020;477:3349-66. [PMID: 32941644 DOI: 10.1042/BCJ20190382] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Lindenberg M, Retèl V, Rohaan M, van den Berg J, Haanen J, van Harten W. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness. BMC Cancer 2020;20:712. [PMID: 32736535 DOI: 10.1186/s12885-020-07166-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
59 Li A, Kusuma GD, Driscoll D, Smith N, Wall DM, Levine BL, James D, Lim R. Advances in automated cell washing and concentration. Cytotherapy 2021;23:774-86. [PMID: 34052112 DOI: 10.1016/j.jcyt.2021.04.003] [Reference Citation Analysis]
60 Qiu T, Wang Y, Liang S, Han R, Toumi M. The impact of COVID-19 on the cell and gene therapies industry: Disruptions, opportunities, and future prospects. Drug Discov Today 2021:S1359-6446(21)00207-5. [PMID: 33892148 DOI: 10.1016/j.drudis.2021.04.020] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Coppens DGM, Hoekman J, De Bruin ML, Slaper-Cortenbach ICM, Leufkens HGM, Meij P, Gardarsdottir H. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries. Cytotherapy 2020;22:592-600. [PMID: 32563611 DOI: 10.1016/j.jcyt.2020.04.092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Master Z, Matthews KRW, Abou-El-Enein M. Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports 2021;16:1435-45. [PMID: 34107243 DOI: 10.1016/j.stemcr.2021.05.004] [Reference Citation Analysis]